Easy To Use Patents Search & Patent Lawyer Directory

At Patents you can conduct a Patent Search, File a Patent Application, find a Patent Attorney, or search available technology through our Patent Exchange. Patents are available using simple keyword or date criteria. If you are looking to hire a patent attorney, you've come to the right place. Protect your idea and hire a patent lawyer.


Search All Patents:



  This Patent May Be For Sale or Lease. Contact Us

  Is This Your Patent? Claim This Patent Now.






Register or Login To Download This Patent As A PDF




United States Patent RE43,279
Benner ,   et al. March 27, 2012

Compositions capable of reducing elevated blood urea concentration

Abstract

The invention includes a method of reducing urea concentration in a subject's serum. Such a method comprises administering to the subject (e.g., a mammal such as a human) a composition comprising an oligopeptide (or oligopeptides) having activity in reducing urea concentration in the subject's serum as determined by a mouse renal reperfusion test, wherein the oligopeptide comprises the sequence AQG or MTRV (SEQ ID NO:1), AQGV (SEQ ID NO:2) or LAGV (SEQ ID NO:4).


Inventors: Benner; Robbert (Barendrecht, NL), Khan; Nisar Ahmed (Rotterdam, NL)
Assignee: Biotemp B.V. (Koekange, NL)
Appl. No.: 13/065,316
Filed: March 17, 2011


Related U.S. Patent Documents

Application NumberFiling DatePatent NumberIssue Date
11249541Oct., 2005
PCT/EP2005/03707Apr., 2005
10821256Apr., 2004
10262522Sep., 20027365155
PCT/NL01/00259Mar., 2001
Reissue of:11346450Feb., 20067576174Aug., 2009

Foreign Application Priority Data

Mar 29, 2000 [EP] 00201139

Current U.S. Class: 530/300 ; 530/330
Current International Class: C07K 2/00 (20060101)

References Cited

U.S. Patent Documents
4977244 December 1990 Muchmore et al.
5010175 April 1991 Rutter et al.
5308834 May 1994 Scott et al.
5380668 January 1995 Herron
5436270 July 1995 Wang
5650489 July 1997 Lam et al.
5677275 October 1997 Lunardi-Iskandar et al.
5801193 September 1998 Ojo-Amaize et al.
5851997 December 1998 Harris
5854004 December 1998 Czernilofsky et al.
5877148 March 1999 Lunardi-Iskandar et al.
5942494 August 1999 Ginsberg et al.
5958413 September 1999 Anagnostopulos et al.
5968513 October 1999 Gallo et al.
5997871 December 1999 Gallo et al.
6022696 February 2000 Harding et al.
6278794 August 2001 Parekh et al.
6319504 November 2001 Gallo et al.
6361992 March 2002 Szkudlinski et al.
6489296 December 2002 Grinnell et al.
6507788 January 2003 Camara y Ferrer et al.
6583109 June 2003 Gallo et al.
6586403 July 2003 Mathison et al.
6596688 July 2003 Gallo et al.
6620416 September 2003 Gallo et al.
6642201 November 2003 Khavinson et al.
6727227 April 2004 Khavinson
6844315 January 2005 Khan et al.
6921751 July 2005 Khan et al.
7175679 February 2007 Khan et al.
7358330 April 2008 Khan et al.
7365155 April 2008 Khan et al.
7402322 July 2008 Khan et al.
7501391 March 2009 Khan et al.
7517529 April 2009 Khan et al.
7524820 April 2009 Khan et al.
7560433 July 2009 Khan et al.
7662776 February 2010 Khan et al.
7786084 August 2010 Benner et al.
7795226 September 2010 Benner et al.
2002/0041871 April 2002 Brudnak
2002/0064501 May 2002 Khan et al.
2002/0147306 October 2002 Lin et al.
2002/0155106 October 2002 Hammond
2003/0049273 March 2003 Gallo et al.
2003/0113733 June 2003 Khan et al.
2003/0119720 June 2003 Khan et al.
2003/0148955 August 2003 Pluenneke
2003/0166556 September 2003 Khan et al.
2003/0186244 October 2003 Margus et al.
2003/0212253 November 2003 Hammond et al.
2003/0215434 November 2003 Khan et al.
2003/0219425 November 2003 Khan et al.
2003/0220257 November 2003 Benner et al.
2003/0220258 November 2003 Benner et al.
2003/0220259 November 2003 Benner et al.
2003/0220260 November 2003 Khan et al.
2003/0220261 November 2003 Khan et al.
2003/0224995 December 2003 Khan et al.
2004/0013661 January 2004 Wensvoort et al.
2004/0208885 October 2004 Khan et al.
2005/0037430 February 2005 Khan et al.
2005/0107314 May 2005 Gorczynski et al.
2005/0119184 June 2005 Khan et al.
2005/0214943 September 2005 Khan et al.
2005/0227925 October 2005 Benner et al.
2006/0111292 May 2006 Khan et al.
2006/0142205 June 2006 Benner et al.
2006/0173162 August 2006 Djurup et al.
2006/0275255 December 2006 Gudkov
2007/0111948 May 2007 Turdiev
Foreign Patent Documents
3715662 Nov., 1987 DE
19953339 May., 2001 DE
0 572 688 May., 1997 EP
1 138 692 Oct., 2001 EP
1 300 418 Apr., 2003 EP
1 224 212 Jul., 2003 EP
2 706 772 Dec., 1994 FR
2 194 886 Mar., 1988 GB
09-176187 Jul., 1997 JP
WO 92/20795 Nov., 1992 WO
96/04008 Feb., 1996 WO
WO 96/33218 Oct., 1996 WO
97/49373 Dec., 1997 WO
97/49418 Dec., 1997 WO
97/49432 Dec., 1997 WO
WO 97/49721 Dec., 1997 WO
WO 98/06742 Feb., 1998 WO
WO 98/34631 Aug., 1998 WO
WO 98/35691 Aug., 1998 WO
WO 99/31227 Jun., 1999 WO
WO 99/59617 Nov., 1999 WO
WO 00/17348 Mar., 2000 WO
WO 01/10907 Feb., 2001 WO
WO 01/11048 Feb., 2001 WO
WO 0110457 Feb., 2001 WO
WO 01/29067 Apr., 2001 WO
WO 01/29069 Apr., 2001 WO
WO 01/32196 May., 2001 WO
WO 01/36454 May., 2001 WO
WO 01/51508 Jul., 2001 WO
WO 01/68113 Sep., 2001 WO
WO 01/72831 Oct., 2001 WO
WO 01/83554 Nov., 2001 WO
WO 02/085117 Oct., 2002 WO
WO 03/029292 Apr., 2003 WO
WO 2004/093897 Nov., 2004 WO
WO 2005/097163 Oct., 2005 WO
WO 2006/069198 Jun., 2006 WO

Other References

Adib-Conquy et al., "NF-.kappa.B Expression in Mononuclear Cells in Patients with Sepsis Resembles That Observed in Lipopolysaccharide Tolerance," Am. J. Respir. Crit. Care Med., 2000, pp. 1877-1883, vol. 162. cited by other .
Agrawal et al., Acute Renal Fai.quadrature.ure, Amer.quadrature.can Family Physician, 2000, pp. 2077-2088, vol. 61, corresponding to web version of p. 1-12. cited by other .
Arima et al., "IL-2-Induced Growth of CD8+ T Cell Prolymphocytic Leukemia Cells Mediated by NF-kappaB Induction and IL-2 Receptor alpha Expression," Leukemia Research, 1998, pp. 265-273, vol. 22, No. 3. cited by other .
Babu, V. V. Suresh (Synthetic Communcaitons 29 (1)m 79-91, 1999. cited by other .
Baeuerle et al., "Function and Activation of NF-.kappa.B in the Immune System," Annu. Rev. Immunol., 1994, pp. 141-179, vol. 12. cited by other .
Barton et al., Protective Role of Interleukin 6 in the Lipopolysaccharide-Galactosamine Septic Shock Model, Infection and Immunity, Apr. 1993, pp. 1496-1499, vol. 61, No. 4. cited by other .
Baud et al., Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain, Genes & Development, May 1999, pp. 1297-1308, vol. 13. cited by other .
Brown et al., "Two Forms of NF-kappaB1 (p105/p50) in Murine Macrophages: Differential Regulation by Lipopolysaccharide, Interleukin-2, and Interferon.quadrature.gamma," Journal of Interferon and Cytokine Research, 1997, pp. 295-306, vol. 17. cited by other .
Capizzi, Investigational New Drugs, 1996, 14:249-256. cited by other .
Cillari et al., (Infection and Immunity, vol. 62, No. 6, p. 2649-2652, Jun. 1994). cited by other .
Cui et al., Am. J. Physiol. Integr. Comp. Physiol., 2004, pp. R699-R709, vol. 286. cited by other .
Daemen et al., Ischemia-reperfusion-induced IFN-gamma up-regulation: involvement of IL-12 and IL-13, The Journal of Immunology, 1999, pp. 5506-5510, vol. 162. cited by other .
De Saizieu et al., Journal of Bacteriology, vol. 182, No. 17, pp. 4696-4703, Sep. 2000. cited by other .
Dechend et al., Oncogene, vol. 18, pp. 3316-3323, 1999. cited by other .
Donnahoo et al., Early kidney TNF-alpha expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion, American Journal of Physiology, Sep. 1999, pp. R922-R929, vol. 277, No. 3, Pt. 2. cited by other .
Dwinnell et al., Atlas of Diseases of the Kidney, Blackwell Sciences, 1999, pp. 12.1-12.12, Ch. 12. cited by other .
Eckardt et al., Hypoxia-induced accumulation of erythropoietin mRNA in isolated hepatocytes is inhibited by protein kinase C, Pflugers Archiv., 1994, pp. 21-30, vol. 426. cited by other .
GenBank Accession No. NP.sub.--000728, GI: 4502789, publicly available Apr. 2007. cited by other .
Hierholzer et al., Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrhagic shock, J. Exp. Med., Mar. 1998, pp. 917-928, vol. 187, No. 6. cited by other .
Huang et al., Ischemia-reperfusion and immediate T cell responses, Cellular Immunology, 2007, pp. 4-11, vol. 248. cited by other .
Husek et al., Rapid screening of urinary proline-hydroxyproline dipeptide in bone turnover studies, Abstract, J. Chromatogr B Analyt Technol Biomed Life Sci., Feb. 5, 2002, pp. 169-174, vol. 767, No. 1. cited by other .
Kalns et al., Biochem. Biophys. Res. Comm., 2002, pp. 41-44, vol. 292. cited by other .
Kalns et al., Biochem. Biophys. Res. Comm., 2002, pp. 506-509, vol. 297. cited by other .
Keeton and Gould, Biological Science, 5th Ed., New York, W.W. Norton & Company, Inc. 1993, p. 4. cited by other .
Lin et al., The Journal of Biological Chemistry, vol. 270, No. 24, pp. 14255-14258, Jun. 1995. cited by other .
Lunardi-Iskandar et al., "Effects of a urinary factor from women in early pregnancy on HIV-a, SIV and associated disease," Nature Medicine, pril 1998, pp. 428-434, vol. 4, No. 4. cited by other .
Merck Index, 17th ed. 1999, pp. 1145-1146, 1841-1848, 2539, 2551. cited by other .
Moayeri et al., Journal of Clinical Investigation, Sep. 2003, pp. 670-682, vol. 112, No. 5. cited by other .
Ohlsson et al., Interleukin-1 Receptor Antagonist Reduces Mortality from Endotoxin Shock, Nature, Dec. 6, 1990, pp. 550-552, vol. 348. cited by other .
Oka et al., Immunosuppression in organ transplantation, Japanese Journal of Pharmacology, vol. 71, No. 2, pp. 89-100, Jun. 1996. cited by other .
Olszyna et al., Levels of Inhibitors of Tumor Necrosis Factor Alpha and Interleukin 1b in Urine and Sera of Patients with Urosepsis, Infection and Immunity, Aug. 1998, pp. 3527-3534. cited by other .
Partial European Search Report for 02 763 111.8 dated Nov. 23, 2007. cited by other .
Riera et al., Neutrophils accentuate renal cold ischemia-reperfusion injury. Dose-dependent protective effect of platelet-activating factor receptor antagonist, The Journal of Pharmacology and Experimental Therapeutics, 1997, pp. 786-794, vol. 280, No. 2. cited by other .
Roice, M. (Tetrahedron 56 (23), 3725-3734, 2000. cited by other .
Van Holde, Physical Biochemistry, pp. 3947, Prentice-Hall, 1971. cited by other .
Wallraff et al., Urinary Excretion of Amino Acids in Pregnancy, J. Clinc. Invest., 1950, pp. 1542-1544, vol. 29. cited by other .
Werner et al., Experientia vol. 42, p. 521-531, 1986). cited by other .
Wu et al., Gonadotropin-Releasing Hormone (GNRH) Cleavage Products are Involved in the Regulation of GNRH Gene Expression in the GT1-7 Neuronal Cell Line, Society for Neuroscience Abstracts, Nov. 4, 2000, pp. 7.8, XP009091566, vol. 26, No. 1-2. cited by other .
U.S. Appl. No. 11/593,329, filed Nov. 6, 2006, Treatment of Ischemic Events. cited by other .
U.S. Appl. No. 11/600,294, filed Nov. 15, 2006, Oligopeptide Acetate and Formulations Thereof. cited by other .
U.S. Appl. No. 11/975,284, filed Oct. 17, 2007, Treatment for Tumors. cited by other .
U.S. Appl. No. 11/981,491, filed Oct. 30, 2007, Treatment of Iatrogenic Disease. cited by other .
U.S. Appl. No. 11/982,292, filed Oct. 31, 2007, Treatment of Neurologicl Disorders. cited by other .
U.S. Appl. No. 11/986,043, filed Oct. 30, 2007, Peptide Compositions. cited by other .
U.S. Appl. No. 12/001,035, filed Dec. 6, 2007, Gene Regulator. cited by other .
Albini, A., et al., "Old drugs as novel angiogenesis inhibitors: Preclinical studies with NAC, hCG, EGCG and somatostatin," 17 Clinical & Experimental Metastasis 739 (1999). cited by other .
Blackwell, Timothy S., et al., "The Role of Nuclear Factor-.kappa.B in Cytokine Gene Regulation," 17 Am. J. Respir. Cell Mol. Biol. 3-9 (1997). cited by other .
Christman et al., Nuclear factor kappaB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy, Intens Care Med, 1998, pp. 1131-1138, vol. 24. cited by other .
Connelly et al., Biphasic Regulation of NF-.kappa.B Activity Underlies the Pro- and Anti-Inflammatory Actions of Nitric Oxide, The Journal of Immunology, 2001, pp. 3873-3881, 166, The American Association of Immunologists, USA. cited by other .
Friedlander, Tackling anthrax, Nature, Nov. 8, 2001, pp. 160-161, vol. 414. cited by other .
Iskandar et al., "Effects of a urinary factor from women in early pregnancy on HIV-1. SIV and associated disease", Nature Medicine, Apr. 1998, vol. 4, No. 4, pp. 428-434. cited by other .
Jyonouchi et al., Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression, J Neuroim., 2001, pp. 170-179, vol. 120. cited by other .
Kachra et al., "Low Molecular Weight Components but Not Dimeric HCG Inhibit Growth and Down-Regulate AP-1 Transcription Factor in Kaposi's Sarcoma Cells," Endocrinology, 1997, pp. 4038-4041, vol. 138, No. 9. cited by other .
Kanungo et al., Advanced Maturation of Heteropneustes Fossilis (Bloch) by Oral Administration of Human Chorionic Gonadotropin, J. Adv. Zool., 1999, pp. 1-5, vol. 20. cited by other .
Keller, S., et al., "Human Chorionic Gonadotropin (hCG) Is a Potent Angiogenic Factor for Uterine Endothelial Cells in Vitro," 20(5-6) Placenta, p. A37 (Jul. 1999). cited by other .
Khan, Nisar A., et al., "Inhibition of Diabetes in NOD Mice by Human Pregnancy Factor," 62(12) Human Immunology 1315-1323 (Dec. 2001). cited by other .
Khan, Nisar A., et al., "Inhibition of Septic Shock in Mice by an Oligopeptide From the .beta.-Chain of Human Chorionic Gonadotrophin Hormone," 63(1) Human Immunology 1-7 (Jan. 2002). cited by other .
Lang et al., "Induction of apoptosis in Kaposi's sarcoma spindle cell cultures by the subunits of human chorionic gonadotropin", AIDS 1997, vol. 11, No. 11, pp. 133-1340. cited by other .
Medzhitov, Toll-like Receptors and Innate Immunity, Nature Reviews/Immunology, Nov. 2001, pp. 135-145, vol. 1. cited by other .
Muchmore et al., Immunoregulatory Properties of Fractions from Human Pregnancy Urine: Evidence that Human Chorionic Gonadotropin is not Responsible, The Journal of Immunology, Mar. 1997, pp. 881-886, vol. 118, No. 3. cited by other .
Muchmore et al., Purification and Characterization of a Mannose-Containing Disaccharide Obtained from Human Pregnancy Urine, Journal of Experimental Medicine, Dec. 1984, pp. 1672-1685, vol. 160. cited by other .
Patil, A., et al., "The Study of the Effect of Human Chorionic Gonadotrophic (HCG) Hormone on the Survival of Adrenal Medulla Transplant in Brain. Preliminary Study," 87 Acta Neurochir (WIEN) 76-78 (1987). cited by other .
Rohrig et al., Growth-stimulating Influence of Human Chorionic Gonadotropin (hCG) on Plasmodium falciparum in vitro, Zentralblatt Bakt, 1999, pp. 89-99, vol. 289. cited by other .
Slater, Lewis M., et al., "Decreased Mortality of Murine Graft-VersUS -Host Disease by Human Chorionic gonadotropin,"23(1) Transplantation 103-104 (Jan. 1977). cited by other .
Tak et al., NF-kappa.beta.: a key role in inflammtory diseases, J Clin Invest., 2001, pp. 7-11, vol. 107. cited by other .
Tan et al., The role of activation of nuclear factor-kappa B of rat brain in the pathogenesis of experimental allergic encephalomyelitis, Acta Physiol Sinica, 2003, pp. 58-64, vol. 55. cited by other .
Tovey et al., Mucosal Cytokine Therapy: Marked Antiviral and Anti-tumor Activity, J. Interferon Cytokine Res., 1999, pp. 911-921, vol. 19. cited by other .
Wulczyn, F. Gregory, et al., "The NF-kB/Rel and IkB gene families: mediators of immune response and inflammation," 74(12) J. Mol. Med. 749-769 (1996). cited by other .
Yamamoto, Y., et al., "Role of the NF-kB Pathway in the Pathogenesis of Human Disease States," 1(3) Current Molecular Medicine 287-296 (Jul. 2001). cited by other .
Ivanov et al., "Hemoglobin as a Source of Endogenous Bioactive Peptides: The Concept of Tissue-Specific Peptide Pool," Biopolymers, 1997, pp. 171-188, vol. 39. cited by other .
Khavinson et al, Gerontological Aspects of Genome Peptide Regulation, 2005, S. Karger AG, Basel, Switzerland. cited by other .
Khavinson et al., "Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People," Bulletin of Experimental Biology and Medicine, Oct. 2002, pp. 389-392, vol. 134, No. 4. cited by other .
Khavinson et al., "Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects," Bulletin of Experimental Biology and Medicine, Jan. 2004, pp. 78-81, vol. 137, No. 1. cited by other .
Khavinson et al., "Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells," Bulletin of Experimental Biology and Medicine, Jun. 2003, pp. 590-592, vol. 135, No. 6. cited by other .
Khavinson et al., "Inductive Activity of Retinal Peptides," Bulletin of Experimental Biology and Medicine, Nov. 2002, pp. 482-484, vol. 134, No. 5. cited by other .
Khavinson et al., "Mechanisms Underlying Geroprotective Effects of Peptides," Bulletin of Experimental Biology and Medicine, Jan. 2002, pp. 1-5, vol. 133, No. 1. cited by other .
Khavinson et al., "Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell,"Bulletin of Experimental Biology and Medicine, May 2004, pp. 503-506, vol. 137, No. 5. cited by other .
Morozov et al., "Natural and Synthetic Thymic Peptides as Therapeutics for Immune Dysfunction," Int. J. Immunopharmac., 1997, pp. 501-505, vol. 19, No. 9/10. cited by other.

Primary Examiner: Kim; Yunsoo
Attorney, Agent or Firm: TraskBritt

Parent Case Text



CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent application Ser. No. 11/249,541, filed on Oct. 13, 2005 now abandoned, which is a continuation-in-part of International Application No. PCT/EP2005/003707, filed on Apr. 8, 2005, designating the United States of America, U.S. patent application Ser. No. 10/821,256, filed on Apr. 8, 2004 now abandoned, and U.S. patent application Ser. No. 10/262,522, filed on Sep. 30, 2002 now U.S. Pat. No. 7,365,155, which itself is a continuation of International Application No. PCT/NL01/00259, (International Publication No. WO 01/72831 A2) filed .[.Mar. 3, 2001.]. .Iadd.Mar. 29, 2001.Iaddend., designating the United States of America, the contents of the entirety of all of which are incorporated by this reference.
Claims



What is claimed is:

1. An isolated oligopeptide consisting of the amino acid sequence of SEQ ID NO: 2 or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 2 or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition of claim 2 further comprising a pharmaceutically acceptable carrier, adjuvant, diluent, excipient or any mixtures thereof.

4. An isolated oligopeptide consisting of the amino acid sequence of SEQ ID NO: 2.
Description



TECHNICAL FIELD

The invention relates generally to biotechnology, and more specifically to compositions having immunoregulatory activity, which compounds include particular oligopeptides derived from human chorionic gonadotropin ("hCG").

BACKGROUND

U.S. Pat. No. 5,380,668 to Herron (Jan. 10, 1995), the contents of the entirety of which are incorporated by this reference, discloses, among other things, various compounds having the antigenic binding activity of hCG. The oligopeptides disclosed therein are disclosed generally for use in diagnostic methods.

Various patents and patent applications to Gallo et al. (e.g., U.S. Pat. No. 5,677,275 (corresponding to WO 96/04008 A1), U.S. Pat. No. 5,877,148 (also corresponding to WO 96/04008 A1), WO 97/49721 A1, U.S. Pat. No. 6,319,504 (corresponding to WO 97/49373), U.S. Patent Application 2003/0049273 A1 (also corresponding to WO 97/49373), U.S. Pat. No. 5,968,513 (corresponding to WO 97/49418), U.S. Pat. No. 5,997,871 (corresponding to WO 97/49432), U.S. Pat. Nos. 6,620,416, 6,596,688, WO 01/11048 A2, WO 01/10907 A2., and U.S. Pat. No. 6,583,109) relate to various oligopeptides and their use in, among other things, "inhibiting HIV infection," "treating or preventing HIV infection," "treating or preventing cancer," "treating or preventing a condition characterized by loss of body cell mass," "treating or preventing a condition associated with pathological angiogenesis," "treating or preventing hematopoietic deficiency," "ex vivo gene therapy," "expanding blood cells in vitro," and/or "providing blood cells to a subject."

DISCLOSURE OF THE INVENTION

As described in PCT International Publication No. WO 03/029292 A2 (published Apr. 10, 2003), PCT International Publication No. WO 01/72831 A2 (published Oct. 4, 2001), and U.S. Patent Application Publications 20020064501 A1 (published May 30, 2002), 20030119720 A1 (published Jun. 26, 2003), 20030113733 A1 (published Jun. 19, 2003), and 20030166556 A1 (published Sep. 4, 2003), the contents of all of which are incorporated by this reference, compositions containing some of the oligopeptides described herein have immunoregulatory activity useful in, for example, the treatment of sepsis and other disease states and conditions.

The invention includes a method of reducing blood urea nitrogen (BUN) concentration (herein also called urea concentration) in a subject's serum. Such a method comprises administering to the subject (e.g., a mammal such as a human) a composition comprising an oligopeptide (or oligopeptides) having activity in reducing urea concentration in the subject's serum as determined by a mouse renal reperfusion test, wherein the oligopeptide comprises the sequence AQG or LAGV (SEQ ID NO:4), or AQGV (SEQ ID NO:2) or MTRV (SEQ ID NO:1)).

The oligopeptide of the composition will typically be from three (3) to twelve (12) amino acids in length. In the case where the composition includes the oligopeptide AQG or LAGV (SEQ ID NO:4) or AQGV (SEQ ID NO:2), the composition may be administered orally. The oligopeptide will preferably be of synthetic origin (e.g., produced by a Merrifield synthesis). When the composition is administered to the subject parenterally, the composition will typically consist essentially of oligopeptide and PBS (e.g., in an amount of from about 0.25 to about 10 mg/kg body mass of the subject).

The invention is thought to be useful for instances, when, for example, the subject is undergoing acute renal failure, especially when the subject is undergoing persistent oliguria, is not producing more than 1/2 ml urine per hour per kilogram body mass of the subject, and/or has a serum potassium level greater than 6.5 mmol per liter serum.

In one preferred embodiment, the invention involves administering a purified, synthetic or isolated peptide consisting of AQGV (SEQ ID NO:2), or an acid addition salt thereof. A typical dosage of this peptide will vary from about 0.5 to about 35 mg/kg body weight of the subject

In another preferred embodiment, typically when a relatively low dosage is preferred, the invention involves administering a purified, synthetic or isolated peptide consisting of AQG, or an acid addition salt thereof at, for example, a dosage of the peptide from about 0.1 to about 10 mg/kg body weight of the subject.

The invention also provides use of a composition according to the invention for the preparation of a pharmnaceutical composition or medicament for the treatment of a disorder such as acute renal failure. Such a composition is preferably prepared using a purified, synthetic or isolated peptide consisting of AQG or AQGV (SEQ ID NO:2) or LAGV (SEQ ID NO:4) or MTRV (SEQ ID NO:1), or an acid addition salt thereof. Most preferably, AQG (when low dosages are preferred) or AQGV (SEQ ID NO:2) is used.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 graphically depicts the results of Example 1. Shown are the BUN (urea) values at the various points in time after treatment with peptides A to F or without treatment (control).

FIG. 2 graphically depicts the results of Example 4. Shown are the BUN (urea) values at the various points in time after treatment with varying dosages of peptide D or peptide B or without treatment (PBS).

FIG. 3 depicts the blood urea values of Example 4 at 0, 24, and 72 hours post-clamping after administration of "peptide D" AQG and "peptide B" AQGV (SEQ ID NO:2). PBS control compared to peptide administered groups.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, a "purified, synthetic or isolated" peptide is one that has been purified from a natural or biotechnological source, or, more preferably, is synthesized as described herein.

"Composition," as used herein, refers to chemical compounds that contain or consist of the oligopeptide. The oligopeptide is preferably isolated before inclusion within the composition. The oligopeptide most preferably consists of three (3) to six (6) amino acids.

For instance, the previously described preferred compound could, in one embodiment be:

TABLE-US-00001 NT A Q G V CT

wherein NT at the N-terminus is selected from the group of H--, CH3--, an acyl group, or a general protective group; and CT at the C-terminus is selected from the group of small (e.g. 1 to 5 amino acids) peptides, --OH, --OR.sup.1, --NH.sub.2, --NHR.sup.1, --NR.sup.1R.sup.2, or --N(CH.sub.2).sub.1-6NR.sup.1R.sup.2, wherein R.sup.1R.sup.2, when present, are independently selected from H, alkyl, aryl, (ar)alkyl, and wherein R.sup.1R.sup.2, can be cyclically bonded to one another.

"Alkyl" as used herein, is preferably a saturated branched or unbranched hydrocarbon having one to six carbon atoms, for example, methyl, ethyl, and isopentyl.

"Aryl" as used herein, is an aromatic hydrocarbon group, preferably having 6 to 10 carbon atoms, such as phenyl or naphthyl.

"(Ar)alkyl" as used herein, is an arene group (having both aliphatic and aromatic portions), preferably having 7 to 13 carbon atoms such as benzyl, ethylbenzyl, n-propylbenzyl, and isobutylbenzyl.

"Oligopeptide" as used herein, are peptides having from 3 to 12 amino acids joined together by peptide bonds. Equivalent to oligopeptides are compounds having the same or equivalent side chains as the particular amino acids used in an oligopeptide, and arranged sequentially in the same order as the peptides, but joined together by non-peptide bonds, e.g., by isosteric linkages such as the keto isostere, hydroxy isostere, diketo isostere, or the keto-difluoromethylene isostere.

"Composition" also includes, for example, an acceptable salt of the oligopeptide or a labeled oligopeptide. As used herein, "acceptable salt" refers to salts that retain the desired activity of the oligopeptide or equivalent compound, but preferably do not detrimentally affect the activity of the oligopeptide or other component of a system in which uses the oligopeptide. Examples of such salts are acid addition salts formed with inorganic acids, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like. Salts may also be formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, and the like. Salts may be formed with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel and the like or with an organic cation formed from N,N'-dibenzylethylenediamine or ethylenediamine, or combinations thereof (e.g., a zinc tannate salt).

The invention also provides use of an oligopeptide having activity in reducing urea concentration in a subject's serum as determined by a mouse renal reperfusion test, the oligopeptide preferably comprising the sequence AQG or MTRV (SEQ ID NO:1) or LAGV (SEQ ID NO:4), in the production of a pharmaceutical composition for reducing urea concentration in a subject's serum, in particular when the subject is undergoing acute renal failure. It is preferred that the oligopeptide to be used in the production of the pharmaceutical composition consists of AQGV (SEQ ID NO:2).

Such a pharmaceutical composition may be administered to the subject parenterally or orally. Such a pharmaceutical composition may consist essentially of oligopeptide and PBS. It is preferred that the oligopeptide is of synthetic origin. Suitable treatment for example entails administering the oligopeptide in the pharmaceutical composition to the patient intravenously in an amount of from about 0.1 to about 35 mg/kg body mass of the subject. It may be useful that the pharmaceutical composition consists essentially of from one to three different oligopeptides.

Such treatment is in particular preferred when the subject is undergoing persistent oliguria, for example when the subject's kidneys are not producing more than 1/2 ml urine per hour per kilogram body mass of the subject, or when the subject has a serum potassium level greater than 6.5 mmol per liter serum.

The thus developed chemical entity can be administered and introduced in-vivo systemically, topically, or locally. The peptide, or its modification or derivative, can be administered as the entity as such or as a pharmaceutically acceptable acid- or base addition salt, formed by reaction with an inorganic acid (such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid); or with an organic acid (such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid); or by reaction with an inorganic base (such as sodium hydroxide, ammonium hydroxide, potassium hydroxide); or with an organic base (such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines). A selected peptide and any of the derived entities may also be conjugated to sugars, lipids, other polypeptides, nucleic acids and PNA; and function in-situ as a conjugate or be released locally after reaching a targeted tissue or organ.

A "substitution" with regard to the various amino acids generally relate to substituting a group such as alkoxy, halogen, hydroxy, nitro, or lower alkyl onto an aromatic ring for hydrogen that would usually be present. Substitutions can also be made on the alkyl chain connecting the aromatic portion to the peptide backbone, with, for instance lower alkyl groups substituting for hydrogen. Still further substitutions can be made at the alpha position of an amino acid, also using an alkyl group.

Preferred substitutions involve the use of fluorine or chlorine as a halogen, and methoxy as an alkoxy group. With regard to alkyl and lower alkyl, generally alkyl groups having fewer (1 to 3) carbon atoms are preferred.

The compounds according to the general formula may be prepared in a manner conventional for such compounds. To that end, suitably N alpha protected (and side-chain protected if reactive side-chains are present) amino acid derivatives or peptides are activated and coupled to suitably carboxyl protected amino acid or peptide derivatives either in solution or on a solid support. Protection of the alpha-amino functions generally takes place by urethane functions such as the acid-labile tertiary-butyloxycarbonyl group ("Boc"), benzyloxycarbonyl ("Z") group and substituted analogs or the base-labile 9-fluoremyl-methyloxycarbonyl ("Fmoc") group. The Z group can also be removed by catalytic hydrogenation. Other suitable protecting groups include the Nps, Bmv, Bpoc, Aloc, MSC, etc. A good overview of amino protecting groups is given in The peptides, Analysis, Synthesis, Biology, Vol. 3 E. Gross and J. Meienhofer, eds. (Academic Press, New York, 1981). Protection of carboxyl groups can take place by ester formation, for example, base-labile esters like methyl or ethyl, acid labile esters like tert. butyl or, substituted, benzyl esters or hydrogenolytically. Protection of side-chain functions like those of lysine and glutamic or aspartic acid can take place using the aforementioned groups. Protection of thiol, and although not always required, of guanidino, alcohol and imidazole groups can take place using a variety of reagents such as those described in The Peptides, Analysis, Synthesis, Biology, id. or in Pure and Applied Chemistry, 59(3), 331-344 (1987). Activation of the carboxyl group of the suitably protected amino acids or peptides can take place by the azide, mixed anhydride, active ester, or carbodiimide method especially with the addition of catalytic and racemization-suppressing compounds like 1-N-N-hydroxybenzotriazole, N-hydroxysuccinimide, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3,-benzotriazine, N-hydroxy-5norbomene-2,3-dicarboxyimide. Also the anhydrides of phosphorus based acids can be used. See, e.g., The Peptides, Analysis, Synthesis, Biology, supra and Pure and Applied Chemistry, 59(3), 331-344 (1987).

It is also possible to prepare the compounds by the solid phase method of Merrifield. Different solid supports and different strategies are known see, e.g. Barany and Merrifield in The Peptides, Analysis, Synthesis, Biology, Vol. 2, E. Gross and J. Meienhofer, eds. (Acad. Press, New York, 1980), Kneib-Cordonier and Mullen Int. J. Peptide Protein Res., 30, 705-739 (1987) and Fields and Noble Int. J. Peptide Protein Res., 35, 161-214 (1990). The synthesis of compounds in which a peptide bond is replaced by an isostere, can, in general, be performed using the previously described protecting groups and activation procedures. Procedures to synthesize the modified isosteres are described in the literature e.g. for the --CH.sub.2--NH-- isostere and for the --CO--CH.sub.2-- isostere.

Removal of the protecting groups, and, in the case of solid phase peptide synthesis, the cleavage from the solid support, can take place in different ways, depending on the nature of those protecting groups and the type of linker to the solid support. Usually deprotection takes place under acidic conditions and in the presence of scavengers. See, e.g. volumes 3, 5 and 9 of the series on The Peptides Analysis, Synthesis, Biology, supra.

Another possibility is the application of enzymes in synthesis of such compounds; for reviews see, e.g., H. D. Jakubke in The Peptides, Analysis, Synthesis, Biology, Vol. 9, S. Udenfriend and J. Meienhofer, eds. (Acad. Press, New York, 1987).

Although possibly not desirable from an economic point of view, oligopeptides according to the invention could also be made according to recombinant DNA methods. Such methods involve the preparation of the desired oligopeptide thereof by means of expressing recombinant polynucleotide sequence that codes for one or more of the oligopeptides in question in a suitable microorganism as host. Generally the process involves introducing into a cloning vehicle (e.g., a plasmid, phage DNA, or other DNA sequence able to replicate in a host cell) a DNA sequence coding for the particular oligopeptide or oligopeptides, introducing the cloning vehicle into a suitable eucaryotic or prokaryotic host cell, and culturing the host cell thus transformed. When a eucaryotic host cell is used, the compound may include a glycoprotein portion.

As used herein, a "functional analogue" or "derivative" of a peptide includes an amino acid sequence, or other sequence monomers, which has been altered such that the functional properties of the sequence are essentially the same in kind, not necessarily in amount. An analogue or derivative can be provided in many ways, for instance, through "conservative amino acid substitution." Also peptidomimetic compounds can be designed that functionally or structurally resemble the original peptide taken as the starting point but that are for example composed of non-naturally occurring amino acids or polyamides. With "conservative amino acid substitution," one amino acid residue is substituted with another residue with generally similar properties (size, hydrophobicity), such that the overall functioning is likely not to be seriously affected. However, it is often much more desirable to improve a specific function. A derivative can also be provided by systematically improving at least one desired property of an amino acid sequence. This can, for instance, be done by an Ala-scan and/or replacement net mapping method. With these methods, many different peptides are generated, based on an original amino acid sequence but each containing a substitution of at least one amino acid residue. The amino acid residue may either be replaced by alanine (Ala-scan) or by any other amino acid residue (replacement net mapping). This way, many positional variants of the original amino acid sequence are synthesized. Every positional variant is screened for a specific activity. The generated data are used to design improved peptide derivatives of a certain amino acid sequence.

A derivative or analogue can also be, for instance, generated by substitution of an L-amino acid residue with a D-amino acid residue. This substitution, leading to a peptide that does not naturally occur in nature, can improve a property of an amino acid sequence. It is, for example, useful to provide a peptide sequence of known activity of all D-amino acids in retro inversion format, thereby allowing for retained activity and increased half-life values. By generating many positional variants of an original amino acid sequence and screening for a specific activity, improved peptide derivatives comprising such D-amino acids can be designed with further improved characteristics.

A person skilled in the art is well able to generate analogous compounds of an amino acid sequence. This can, for instance, be done through screening of a peptide library. Such an analogue has essentially the same functional properties of the sequence in kind, not necessarily in amount. Also, peptides or analogues can be circularized, for example, by providing them with (terminal) cysteines, dimerized or multimerized, for example, by linkage to lysine or cysteine or other compounds with side-chains that allow linkage or multimerization, brought in tandem- or repeat-configuration, conjugated or otherwise linked to carriers known in the art, if only by a labile link that allows dissociation.

Synthetic versions of these oligopeptides as described above, and functional analogues or derivatives or breakdown products, are herein provided to lower BUN concentration be used in methods to the treatment of disease.

The term "pharmaceutical composition" as used herein is intended to cover both the active composition of the invention alone or a composition containing the composition of the invention together with a pharmaceutically acceptable carrier, diluent or excipient. Acceptable diluents of an oligopeptide as described herein in the detailed description are for example physiological salt solutions or phosphate buffered salt solutions. In one embodiment, an oligopeptide or composition is administered in an effective concentration to an animal or human systemically, for example, by intravenous, intra-muscular or intraperitoneal administration. Another way of administration comprises perfusion of organs or tissue, be it in vivo or ex vivo, with a perfusion fluid comprising an oligopeptide or composition according to the invention. The administration may be done as a single dose, as a discontinuous sequence of various doses, or continuously for a period of time sufficient to permit substantial modulation of gene expression. In the case of a continuous administration, the duration of the administration may vary depending upon a number of factors that would readily be appreciated by those skilled in the art.

The administration dose of the active molecule may be varied over a fairly broad range. The concentrations of an active molecule that can be administered would be limited by efficacy at the lower end and the solubility of the compound at the upper end. The optimal dose or doses for a particular patient should and can be determined by the physician or medical specialist involved, taking into consideration well-known relevant factors such as the condition, weight and age of the patient, etc.

The active molecule may be administered directly in a suitable vehicle, such as, for example, phosphate-buffered saline ("PBS") or solutions in alcohol or DMSO. Pursuant to preferred embodiments of the present invention, however, the active molecule is administered through a single dose delivery using a drug-delivery system. A suitable drug-delivery system would be pharmacologically inactive or at least tolerable. It should preferably not be immunogenic nor cause inflammatory reactions, and should permit release of the active molecule so as to maintain effective levels thereof over the desired time period. Alternatives are known in the art as suitable for purposes of sustained release and are contemplated as within the scope of the present invention. Suitable delivery vehicles include, but are not limited to, the following: microcapsules or microspheres; liposomes and other lipid-based release systems; viscous instillates; absorbable and/or biodegradable mechanical barriers and implants; and polymeric delivery materials, such as polyethylene oxide/polypropylene oxide block copolymers, polyesters, crosslinked polyvinyl alcohols, polyanhydrides, polymethacrylate and polymethacrylamide hydrogels, anionic carbohydrate polymers, etc. Useful delivery systems are well known in the art.

One formulation to achieve the active molecule release comprises injectable microcapsules or microspheres made from a biodegradable polymer, such as poly(dl-lactide), poly(dl-lactide-co-glycolide), polycaprolactone, polyglycolide, polylactic acid-co-glycolide, poly(hydroxybutyric acid), polyesters or polyacetals. Injectable systems comprising microcapsules or microspheres having a diameter of about 50 to about 500 micrometers offer advantages over other delivery systems. For example, they generally use less active molecules and may be administered by paramedical personnel. Moreover, such systems are inherently flexible in the design of the duration and rate of separate drug release by selection of microcapsule or microsphere size, drug loading and dosage administered. Further, they can be successfully sterilized by gamma irradiation.

The design, preparation, and use of microcapsules and microspheres are well within the reach of persons skilled in the art and detailed information concerning these points is available in the literature. Biodegradable polymers (such as lactide, glycolide and caprolactone polymers) may also be used in formulations other than microcapsules and microspheres; e.g., pre-made films and spray-on films of these polymers containing the active molecule would be suitable for use in accordance with the present invention. Fibers or filaments comprising the active molecule are also contemplated as within the scope of the present invention.

Another highly suitable formulation for a single-dose delivery of the active molecule in accordance with the present invention involves liposomes. The encapsulation of an active molecule in liposomes or multilamellar vesicles is a well-known technique for targeted drug delivery and prolonged drug residence. The preparation and use of drug-loaded liposomes is well within the reach of persons skilled in the art and well documented in the literature.

Yet another suitable approach for single-dose delivery of an active molecule in accordance with the present invention involves the use of viscous installates. In this technique, high molecular weight carriers are used in admixture with the active molecule, giving rise to a structure that produces a solution with high viscosity. Suitable high molecular weight carriers include, but are not limited to, the following: dextrans and cyclodextrans; hydrogels; (cross-linked) viscous materials, including (cross-linked) viscoelastics; carboxymethylcellulose; hyaluronic acid; and chondroitin sulfate. The preparation and use of drug-loaded viscous instillates is well known to persons skilled in the art.

Pursuant to yet another approach, the active molecule may be administered in combination with absorbable mechanical barriers such as oxidized regenerated cellulose. The active molecule may be covalently or non-covalently (e.g., ionically) bound to such a barrier, or it may simply be dispersed therein.

The invention is further explained with the aid of the following illustrative examples.

EXAMPLES

Example 1

Six oligopeptides (i.e., A: LAGV (SEQ ID NO:4), B: AQGV (SEQ ID NO:2), C: LAG, D: AQG, E: MTR, and F: MTRV (SEQ Ip NO:1)) were tested and compared with PBS (control) in a double blind animal study for each peptide's relative ability to aid recovery in a mouse renal ischemia reperfusion test. In this test, the mice were anesthetized, and one kidney from each mouse was removed. The other kidney was tied off for 25 minutes, and the serum urea levels were allowed to increase. Both before and after tying off, each of the separate peptides was administered to thirty (30) different mice (5 mg oligopeptide/kg body mass intravenously), after which, the mortality of the mice was determined for each oligopeptide as well as was the BUN concentration at two hours, 24 hours and 72 hours. The results are shown in FIG. 1 and (excluding the results of peptide A (LAGV (SEQ ID NO:4)) obtained in example 1) in Table 2 below.

Under inhalation anesthesia, the left kidney with its artery and vein was isolated and occluded for 25 minutes using a microvascular clamp. During surgery animals were placed on a heating path to maintain body temperature at 37.degree. C. Five minutes before placing the clamp, and 5 minutes before releasing the clamp, 5 mg/kg of peptide, dissolved in 0.1 mL of sterile saline, was administered intravenously. After reperfusion of the left kidney the right kidney was removed. Kidney function was assessed by measuring blood urea nitrogen before clamping, and at 2, 24, and 72 hours after reperfusion.

TABLE-US-00002 TABLE 1 Results - (mortality at 72 hours post-reperfusion). PBS A B F (LAGV) (AQGV) (MTRV) (SEQ ID (SEQ ID C D E (SEQ ID NO: 4) NO: 2) (LAG) (AQG) (MTR) NO: 1) 6/10 6/10 0/10 4/10 4/10 4/10 2/10 *P < (vs PBS) NS 0.01 0.01 0.01 0.01 0.01 *2 .times. 2 Chi-square test. df = 1

Peptide A (SEQ ID NO:4) was the first peptide administered in the renal ischemia reperfusion test. The personnel who performed the experiments went through a learning curve while working with peptide A (SEQ ID NO:4). During administration of the peptide in the inferior caval vein, some animals experienced moderate blood loss from the site of injection, whereas others did not. Inadvertently the animals were returned to the stable without drinking water present in their cages the first night after surgery. Also, by mistake, the animals that were intended to be sacrificed at 72 h were killed 48 h after reperfusion. None of these or other problems were encountered during the experiments with peptides B-F. (See, Example 2)

As can be seen, mice administered the oligopeptides MTRV (SEQ ID NO:1) and especially AQGV (SEQ ID NO:2) did much better in terms of both survival (a significant reduction in mortality versus the PBS control group) and reduced BUN concentration than the control group (PBS) or the group administered the other oligopeptides, with more mice surviving and the serum urea levels being much lower than in the other groups. However, the oligopeptides LAG, AQG, and MTR, in this experiment having no reducing effect on BUN concentration, each caused a significant reduction of mortality compared to the PBS control, where MTR did significantly raise BUN levels in the tested mice at 72 hrs.

Example 2

One oligopeptide (A: (LAGV (SEQ ID NO:4))) was retested for its capacity to reduce BUN levels in the mice test for the reasons as described above. The results are shown in Table 2 below. As can be seen, mice administered the oligopeptide LAGV (SEQ ID NO:4) now did much better in terms of both survival (a significant reduction in mortality versus the PBS control group) and reduced BUN concentration than the control group (PBS).

Example 3

Four additional oligopeptides (G (VLPALPQ (SEQ ID NO:5)), H (VLPALP (SEQ ID NO:6)), I LQGV (SEQ ID NO:3) and J (LQG)) were tested for there capacity to reduce BUN levels in the mice test as described above. The results are shown in Table 2 below. As can be seen, mice administered the oligopeptide LQG did show reduced BUN concentration early in the experiment (at 24 hours post-reperfusion) and mice administered VLPALPQ (SEQ ID NO:5) did much better in terms of reduced BUN concentration late in the experiment (at 72 hours post-reperfusion) than the control group (PBS) or the group administered the other oligopeptides, with more mice surviving and the serum urea levels being much lower than in the other groups.

TABLE-US-00003 TABLE 2 BUN after 25 min renal ischemia tested in mice with peptides A-J C-term: CARBOXYL Peptide t = 0 hr 2 hr 24 hr 72 hr N-term: FREE A Mean 8.166667 14.03333 38.86364 32.8875 NMPF-47 LAGV (SEQ ID NO: 4) sd 1.774658 1.011599 14.54711 14.31228 N 18 3 11 8 B Mean 9.713333 16.62 26.36 22.31 NMPF-46 AQGV (SEQ ID NO: 2) sd 1.882722 2.185203 20.62105 15.96444 N 30 10 20 10 C Mean 10.15185 18.13333 59.24375 74.4 NMPF-44 LAG SD 1.789794 1.88326 16.19662 33.12546 N 29 6 16 6 D Mean 9.303846 17.7 66.75625 91.18333 NMPF-43 AQG SD 1.502127 1.561135 24.50445 51.22154 N 26 8 16 6 E mean 8.403846 17.13 66.23333 104.0167 NMPF-12 MTR SD 1.739076 1.625526 17.55069 48.97193 N 26 10 6 6 F mean 7.462963 15.08571 34.57368 39.8375 NMPF-11 MTRV(SEQ ID NO: 1) SD 1.338526 1.422941 15.18083 21.45973 N 30 7 18 8 G mean 8.256667 13.58 37.79375 37.6375 NMPF-7 VLPALPQ (SEQ ID NO: 5) SD 1.304021 1.927462 18.33007 29.32872 N 30 7 18 8 H mean 8.423333 16.24 62.4 47.05 NMPF-6 VLPALP (SEQ ID NO: 6) SD 1.255521 1.370482 13.33867 20.92728 N 30 10 9 7 I mean 7.518182 17.53333 56.08333 73.17778 NMPF-4 LQGV (SEQ ID NO: 3) SD 1.537356 2.956913 14.53573 23.3083 N 22 3 18 9 J mean 7.82069 16.75 26.74 83.95714 NMPF-3 LQG SD 1.330515 1.44123 15.51796 40.32129 N 29 8 9 8 PBS mean 8.172414 15.0875 56.81 82.075 control SD 1.549169 2.215167 22.4659 34.82713 N 29 8 15 4

At 24 hour post-reperfusion statistical analyses revealed P-values of:

TABLE-US-00004 A p = 0.0491 NMPF-47 LAGV (SEQ ID NO: 4) B p = 0.0008 NMPF-46 AQGV (SEQ ID NO: 2) C p = 0.9248 NMPF-44 LAG D p = 0.4043 NMPF-43 AQG E p = 0.1848 NMPF-12 MTR F p = 0.0106 NMPF-11 MTRV (SEQ ID NO: 1) G p = 0.1389 NMPF-7 VLPALPQ (SEQ ID NO: 5) H p = 0.5613 NMPF-6 VLPALP (SEQ ID NO: 6) I p = 0.9301 NMPF-4 LQGV (SEQ ID NO: 3) J p = 0.0030 NMPF-3 LQG

At 24 hour post-reperfusion statistical analyses revealed P-values of:

TABLE-US-00005 A p = 0.0017 NMPF-47 LAGV (SEQ ID NO: 4) B p < 0.0001 NMPF-46 AQGV (SEQ ID N0: 2) C p = 0.8186 NMPF-44 LAG D p = 0.2297 NMPF-43 AQG E p = 0.0242 NMPF-12 MTR F p = 0.0021 NMPF-11 MTRV (SEQ ID NO: 1) G p = 0.0049 NMPF-7 VLPALPQ (SEQ ID N0: 5) H p = 0.3297 NMPF-6 VLPALP (SEQ ID N0: 6) I p = 0.8328 NMPF-4 LQGV (SEQ ID N0: 3) J p = 0.9445 NMPF-3 LQG

P values were calculated by Mann Whitney U-test (SPSS for Windows).

Example 4

To determine dose-response relationships, two peptides (D (AQG, having a good effect on mortality on the mice tested in Example 1) and B (AQGV (SEQ ID NO:2), also having superior effect on BUN of the mice tested in Example 1) were also tested in a dose-response manner in the mice test as described above. Peptides were tested at 0.3, 1, 3, 10 and 30 mg/kg dosages given as described in Example 1. The results can be seen in FIG. 2. P values (calculated by Mann Whitney U-test (SPSS for Windows)) of serum urea levels of PBS compared to peptide D groups at 72 hours post-clamping were at 0.3 mg/kg 0.001, at 1 mg/kg 0.009, at 3 mg/kg 0.02, at 10 mg/kg 0.000, and at 30 mg/kg 0.23, for peptide B groups these P-values were 0.88, 0.054, 0.000, 0.001 and 0.003. As can be seen, peptide D (AQG) did reduce BUN levels surprisingly well at the lower dosages tested, as compared with peptide B (AQGV (SEQ ID NO:2)), while the beneficial effect on mortality was also still notable at the lower dosages tested.

TABLE-US-00006 TABLE 3 Mortality in dose-response experiment 24 h 72 h PBS 0-9 4-8 AQG 0.3 mg/kg 0-10 2-8 AQG 1.0 mg/kg 0-10 1-8 AQG 3.0 mg/kg 0-10 0-10 AQG 10.0 mg/kg 0-8 1-10 AQG 30.0 mg/kg 0-8 1-8 AQGV (SEQ ID NO: 2) 0.3 mg/kg 0-9 2-10 AQGV (SEQ ID NO: 2) 1.0 mg/kg 0-10 1-8 AQGV (SEQ ID NO: 2) 3.0 mg/kg 1-10 0-10 AQGV (SEQ ID NO: 2) 10.0 mg/kg 0-10 0-8 AQGV (SEQ ID NO: 2) 30.0 mg/kg 0-8 3-10

TABLE-US-00007 TABLE 4 Urea Levels in dose-response experiment 24 h 72 h PBS 57.8 85.4 Peptide D (AQG) 0.3 mg/kg 38.4 30.4 Peptide D (AQG) 1.0 mg/kg 48.4 38.4 Peptide D (AQG) 3.0 mg/kg 39.3 40.3 Peptide D (AQG) 10.0 mg/kg 46.8 25.8 Peptide D (AQG) 30.0 mg/kg 52.8 58.9 Peptide B (AQGV (SEQ ID NO: 2)) 0.3 mg/kg 62.4 86.7 Peptide B (AQGV (SEQ ID NO: 2)) 1.0 mg/kg 50.0 52.6 Peptide B (AQGV (SEQ ID NO: 2)) 3.0 mg/kg 37.4 19.6 Peptide B (AQGV (SEQ ID NO: 2)) 10.0 mg/kg 41.2 37.1 Peptide B (AQGV (SEQ ID NO: 2)) 30.0 mg/kg 47.8 38.0 standard error PBS 7.1 14.7 Peptide D (AQG) 0.3 mg/kg 8.6 3.5 Peptide D (AQG) 1.0 mg/kg 7.2 10.2 Peptide D (AQG) 3.0 mg/kg 3.5 10.7 Peptide D (AQG) 10.0 mg/kg 8.0 3.4 Peptide D (AQG) 30.0 mg/kg 9.5 12.9 Peptide B (AQGV (SEQ ID NO: 2)) 03 mg/kg 10.8 14.1 Peptide B (AQGV (SEQ ID NO: 2)) 1.0 mg/kg 11.7 14.3 Peptide B (AQGV (SEQ ID NO: 2)) 3.0 mg/kg 7.6 2.6 Peptide B (AQGV (SEQ ID NO: 2)) 10.0 mg/kg 8.5 6.9 Peptide B (AQGV (SEQ ID NO: 2)) 30.0 mg/kg 5.8 7.8

TABLE-US-00008 TABLE 5 statistical significance/p values (Mann Whitney U-Test) of serum urea levels in dose-response experiment 72 hours post-clamping. PBS control compared to peptide administered groups. (See, FIG. 3). 72 h PBS NA AQG 0.3 mg/kg 0.001 AQG 1.0 mg/kg 0.009 AQG 3.0 mg/kg 0.02 AQG 10.0 mg/kg 0.000 AQG 30.0 mg/kg 0.23 AQGV (SEQ ID NO: 2) 0.3 mg/kg 0.88 AQGV (SEQ ID NO: 2) 1.0 mg/kg 0.054 AQGV (SEQ ID NO: 2) 3.0 mg/kg 0.000 AQGV (SEQ ID NO: 2) 10.0 mg/kg 0.001 AQGV (SEQ ID NO: 2) 30.0 mg/kg 0.003

>

6tificial SequenceSynthesized Peptide r Arg Valrtificial SequenceSynthesized Peptide 2Ala Gln Gly Valrtificial SequenceSynthesized Peptide 3Leu Gln Gly Valrtificial SequenceSynthesized Peptide 4Leu Ala Gly Valrtificial SequenceSynthesized Peptide 5Val Leu Pro Ala Leu Pro GlnTArtificial SequenceSynthesized Peptide 6Val Leu Pro Ala Leu Pro>
* * * * *

File A Patent Application

  • Protect your idea -- Don't let someone else file first. Learn more.

  • 3 Easy Steps -- Complete Form, application Review, and File. See our process.

  • Attorney Review -- Have your application reviewed by a Patent Attorney. See what's included.